ACE and Hyperkalemia: In patients with diabetes being treated with an ACE inhibitor, ARB, or spironolactone, compared with no monitoring, regular monitoring of serum potassium has been shown to decrease the risk of hyperkalemia-related adverse events (adjusted relative risk 0.5, 95% CI 0.37–0.66) [64].